Carterra- LSA platform - Crunchbase Company Profile & Funding

Overview

Carterra- LSA platform

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Carterra- LSA platform

CB Rank

642157

Carterra- LSA platform is a disruptive technology for mAb Screening and Characterization.

Acquired by

ImmunoPrecise Antibodies

Founded

obfuscation

Private

Salt Lake City, Utah, United States

carterra-bio.com/lsa

Biotechnology

Information Services

Details

Sub-Organization of

Carterra

Also Known As

Carterra-LSA Instrument

Operating Status

Active

Company Type

For Profit

About the Company

Carterra- LSA platform is a versatile, fully integrated, high throughput monoclonal antibody (mAb) characterization platform that combines patented flow printing microfluidics with high throughput surface plasmon resonance (SPR) detection to deliver up to 100x the data in 10% of the time and with 1% of the sample requirements and consumable costs

of other systems.

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Carterra LSA Platform

A high-throughput monoclonal antibody characterization system using surface plasmon resonance to analyze binding kinetics, affinity, and epitope interactions with minimal sample consumption.

Carterra LSA XT Platform

An enhanced version of the LSA platform offering increased sensitivity and throughput for screening and characterizing antibodies, small molecules, kinases, and protein interactions using high-throughput SPR.